Search
Bufexamac
go.drugbank.com/drugs/DB13346ApprovedWithdrawnBufexamac was also withdrawn by the EMA in April 2010. … The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822].
Quizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigational[A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo. … positive results from the QuANTUM-First trial for FLT3-ITD positive AML, where quizartinib combined with standard cytarabine and anthracycline induction and standard cytarabine consolidation, followed by
Acetylcholine
go.drugbank.com/drugs/DB03128ApprovedInvestigationalIt is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.
Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14450ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Mixtures: FLUZONE High-DoserhMBL
go.drugbank.com/drugs/DB05237InvestigationalMBL forms different oligomers but must form at least a tetramer to be active. … rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL).
Clavulanic acid
go.drugbank.com/drugs/DB00766ApprovedInvestigationalVet approvedClavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin] to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening
Isosorbide
go.drugbank.com/drugs/DB09401ApprovedInvestigationalIt was approved by the FDA in 1980, but has since been discontinued.
Levopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnIt was sold as an antitussive, but it was removed from the market in the 70s.[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962.
Brodalumab
go.drugbank.com/drugs/DB11776ApprovedInvestigationalBrodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-sever...
Clarithromycin
go.drugbank.com/drugs/DB01211ApprovedInvestigationalClarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit.